Aligos Therapeutics (ALGS) risk factors
Item 1A of every Aligos Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors106 risks12 new13 dropped21 reworded
Aligos highlights going concern doubts with cash runway only through the third quarter of 2026. International operations face escalating tariff threats, supply chain complexities, and foreign regulatory hurdles. Intellectual property and licensing dependencies remain critical, notably a $9.0 million payment made to Emory University.
Filed Mar 05, 2026 - FY2024 10-K risk factors107 risks
Aligos Therapeutics faces high commercial risks centered on early-stage clinical development of treatments for CHB, MASH, and COVID-19. The company relies heavily on additional financing, faces intense biopharmaceutical competition, and has never generated product sales revenue.
Filed Mar 10, 2025